News | Mammography | June 14, 2019

Fujifilm Announces Nationwide Breast Health Campaign With Mobile Mammography Coach

Eighteen-month, 48-state campaign looks to improve access to breast health education and mammography screening services

Fujifilm Announces Nationwide Breast Health Campaign With Mobile Mammography Coach

At the center of the campaign, Fujifilm will be traveling around the U.S. with its "Aspire to Be Fearless" mobile mammography coach to provide educational opportunities for clinicians, raise awareness about the importance of screening and will be providing mammograms to the underserved population in key locations.

June 14, 2019 — Fujifilm Medical Systems U.S.A. Inc. announced a nationwide awareness campaign titled ‘Aspire to Be Fearless’ focused on improving access to breast health education and mammography screening services for every woman that needs it, especially those most reluctant. At the center of the campaign, Fujifilm will be traveling around the U.S. with its ‘Aspire to Be Fearless’ mobile mammography coach to provide educational opportunities for clinicians, raise awareness about the importance of screening and will be providing mammograms to the underserved population in key locations.

Fujifilm kicked-off the campaign by supporting an educational event, the Pink Table Brunch, on June 12, 2019 in Portland, Ore. The event featured experts in the field of health, nutrition and breast care. Each presenter shared the latest information about what participants need to know in order to help lessen the fear if they or a loved one is diagnosed with breast cancer. Nisha Jackson, Ph.D., author of a new book entitled “Brilliant Burnout,” signed her latest book at the event.

According to Fujifilm, breast cancer is one of the most feared cancers among women and some women may feel so apprehensive that they put off their breast exams.1 National Cancer Institute statistics show 1 in 8 women may be diagnosed with breast cancer at some time during her life2. Finding breast cancer early and getting state-of-the-art cancer treatment are the most important strategies to prevent deaths from breast cancer.3  Women whose breast cancer is detected at an early stage have on average a 90 percent survival rate in the first five years.4 Unfortunately, minority women are more likely to be diagnosed at a later stage of breast cancer, in part due to barriers to timely screening mammography, resulting in poorer mortality and survival outcomes.5

The ‘Aspire to Be Fearless’ mobile mammography coach will be equipped with a waiting room, dressing room, Aspire Cristalle digital mammography system with digital breast tomosynthesis and Aspire Bellus II mammography diagnostic workstation. Mammography screening services will be available beginning fall 2019. A series of educational events will be hosted by Fujifilm throughout the year in select markets around the country, reaching 48 states over the course of 18 months.

For more information please visit www.fujimed.com

 

References

1.  “Overcoming the Fear of Breast Cancer.” HealthyWomen.Org. Retrieved from https://www.healthywomen.org/content/article/overcoming-fear-breast-cancer

2. “Breast Cancer Risk in American Women.” National Cancer Institute. Retrieved from https://www.cancer.gov/types/breast/risk-fact-sheet

3. “American Cancer Society Recommendations for the Early Detection of Breast Cancer.” American Cancer Society. Retrieved from https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html

4. “Survival Rates for Breast Cancer.”  American Cancer Society.” Retrieved from https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html

5. “Gendered and Racialized Social Expectations, Barriers, and Delayed Breast Cancer Diagnosis” Cancer Journal (September 24, 2018).  Retrieved from https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.31636?purchase_referrer=www.breastcancer.org&tracking_action=preview_click&r3_referer=wol&show_checkout=1

Related Content

Densitas Inc., a global provider of A.I. technologies for digital mammography and breast screening, announced its partnership with Mammography Educators to offer the first artificial intelligence powered telehealth technologist training platform to support business continuity in mammography facilities.
News | Mammography | November 20, 2020
November 20, 2020 — Densitas Inc., a global provider of A.I.
Radiologists around the world will have access to a first-of-its-kind online breast density training tool designed to improve radiologists' ability to correctly identify women's breast density categories to comply with the Breast Imaging-Reporting and Data System (BI-RADS), thanks to a collaboration between DetectED-X and Volpara Health. 
News | Breast Density | November 19, 2020
November 19, 2020 — Radiologists around the world will have access to a first-of-its-kind online...
Reduces the complexity of reporting for screening and diagnostic MRI eams to deliver time-saving and patient safety benefits
News | MRI Breast | November 18, 2020
November 18, 2020 — ...
An interview with Professor Christiane Kuhl, M.D., director of radiology, University Hospital Aachen, Germany, on the effects on breast imaging in the COVID-19 era

Getty Images

Feature | Breast Imaging | November 12, 2020 | By Dave Fornell
The pandemic forced many elective procedures, including most areas of...
Images in a 55-year-old woman with a spiculated mass localized in the upper central quadrant (arrow in A, B, D, and E) of right breast detected with digital breast tomosynthesis (DBT) plus synthetic mammography (SM). Breast density was classified as category C with the Breast Imaging Reporting and Data System. Mass was invasive ductal carcinoma, stage I, and was estrogen and progesterone receptor positive and human epidermal growth factor receptor 2 negative. A, Image from SM in craniocaudal view. B, Single

Images in a 55-year-old woman with a spiculated mass localized in the upper central quadrant (arrow in A, B, D, and E) of right breast detected with digital breast tomosynthesis (DBT) plus synthetic mammography (SM). Breast density was classified as category C with the Breast Imaging Reporting and Data System. Mass was invasive ductal carcinoma, stage I, and was estrogen and progesterone receptor positive and human epidermal growth factor receptor 2 negative. A, Image from SM in craniocaudal view. B, Single-slice DBT image in craniocaudal view. C, Magnification of the lesion depicted in B. D, Image from SM in mediolateral oblique view. E, Single-slice DBT image in mediolateral oblique view. F, Magnification of the lesion depicted in E. Images courtesy of Radiological Society of North America

News | Breast Imaging | November 11, 2020
November 11, 2020 — ...
Hologic, Inc. announced innovative updates to its Unifi Analytics platform, a breakthrough business intelligence tool that provides mammography centers insights into technologist performance, proactive device maintenance, and business considerations.
News | Mammography | November 10, 2020
November 10, 2020 — Hologic, Inc.
Honoring essential healthcareprofessionals, Nov. 8-14
News | Radiology Imaging | November 09, 2020
November 9, 2020 — As COVID-19 continues to spre
Mammograms in a 51-year-old woman with invasive ductal carcinoma. The upper panels show the craniocaudal and the mediolateral oblique views. The lower panels show a close-up of the left breast area containing the lesion. The case is one of the false-negative cases included in the dataset. Accordingly, the initial screening assessment was a BI-RADS 2, meaning visible findings were judged as benign. After 1 year, the patient presented for another screening examination. This time, a focal asymmetry with associ

Mammograms in a 51-year-old woman with invasive ductal carcinoma. The upper panels show the craniocaudal and the mediolateral oblique views. The lower panels show a close-up of the left breast area containing the lesion. The case is one of the false-negative cases included in the dataset. Accordingly, the initial screening assessment was a BI-RADS 2, meaning visible findings were judged as benign. After 1 year, the patient presented for another screening examination. This time, a focal asymmetry with associated distortion within the left breast was noticed; the patient was recalled and diagnosed with a 1.5-cm mass in the upper outer quadrant of the left breast on the craniocaudal view (circle).

News | Mammography | November 04, 2020
November 4, 2020 — Artificial intelligen...